Aurinia Pharmaceuticals Stock News

The last few weeks have seen a lot of buyout chatter on AUPH.

Aurinia won approval for Lupus Nephritis therapy LUPKYNIS in January this year, causing its share price to reach a high of $19.

Aurinia Pharma (AUPH) stock is taking a beating on Monday following a filing with the SEC after markets closed on Friday. The post AUPH Stock: 13 Things to Know About Aurinia Pharma as Shares Crash To

The company's recently filed unlimited shelf registration statement is making shareholders queasy.

The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) fell by over 10% pre-market today. This is why it happened.

Lupus Therapeutic Market report considers the latest upgrades while assessing the development of leading market players. This global market report is comprehensive and opens a door of worldwide market for the products. The report gives helpful insights which assist while

A $250 mixed shelf offering isn't sitting well with the biotech's shareholders.

A $250 mixed shelf offering isn't sitting well with the biotech's shareholders.

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

Aurinia Pharmaceuticals Inc. (TSE:AUP) (NASDAQ:AUPH) Director Michael Robert Martin sold 50,000 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Tuesday, November 9th. The stock was sold at an average price of C$39.82, for a total value of C$1,991,220.00. Following the sale, the director now directly owns 92,824 shares in the company, valued []

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) fell 7.7% during trading on Monday following insider selling activity. The company traded as low as $27.30 and last traded at $27.46. 86,839 shares changed hands during trading, a decline of 98% from the average session volume of 4,182,062 shares. The stock had previously closed at $29.76. Specifically, insider Neil []

Related Stocks: GM , SYY , MEDP , CBOE , MPWR , DKNG , GE , SE , EVCM , BBWI , DASH , AUPH , BABA , JD , EDU , QTS , ALXN , EAR ,

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) have earned a consensus rating of Hold from the seven ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The []